{"id":380825,"date":"2020-11-13T08:35:55","date_gmt":"2020-11-13T13:35:55","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380825"},"modified":"2020-11-13T08:35:55","modified_gmt":"2020-11-13T13:35:55","slug":"contrafect-reports-third-quarter-2020-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-reports-third-quarter-2020-financial-results-and-provides-business-update\/","title":{"rendered":"ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n CARB-X<\/em>
\n <\/strong>
\n
\n and Cystic Fibrosis Foundation<\/em>
\n <\/strong>
\n
\n grant<\/em>
\n <\/strong>
\n
\n s<\/em>
\n <\/strong>
\n
\n provide significant<\/em>
\n <\/strong>
\n
\n additional<\/em>
\n <\/strong>
\n
\n funding to advance <\/em>
\n <\/strong>
\n
\n CF-370 for Pseudomonas aeruginosa infections<\/em>
\n <\/strong>
\n \n <\/p>\n

\n
\n Initiated <\/em>
\n <\/strong>
\n
\n e<\/em>
\n <\/strong>
\n
\n xpanded <\/em>
\n <\/strong>
\n
\n a<\/em>
\n <\/strong>
\n
\n ccess <\/em>
\n <\/strong>
\n
\n p<\/em>
\n <\/strong>
\n
\n rogram<\/em>
\n <\/strong>
\n
\n with<\/em>
\n <\/strong>
\n
\n exebacase for <\/em>
\n <\/strong>
\n
\n the <\/em>
\n <\/strong>
\n
\n t<\/em>
\n <\/strong>
\n
\n reatment of <\/em>
\n <\/strong>
\n
\n p<\/em>
\n <\/strong>
\n
\n ersistent MRSA <\/em>
\n <\/strong>
\n
\n b<\/em>
\n <\/strong>
\n
\n loodstream <\/em>
\n <\/strong>
\n
\n i<\/em>
\n <\/strong>
\n
\n nfections in COVID-19 <\/em>
\n <\/strong>
\n
\n p<\/em>
\n <\/strong>
\n
\n atients<\/em>
\n <\/strong>\n <\/p>\n

YONKERS, New York, Nov. 13, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation<\/strong><\/a> (Nasdaq: CFRX)<\/strong> a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2020.<\/p>\n

\u201cWe are pleased with the progress of the Phase 3 DISRUPT superiority study of exebacase, which received Breakthrough Therapy designation from the FDA earlier this year, in patients suffering from life-threatening Staph aureus<\/em> bloodstream infections,\u201d said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect. \u201cWe also continue to advance our pipeline programs towards the clinic and appreciate the tremendous financial support from CARB-X and the Cystic Fibrosis Foundation for our second product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginos<\/em>a<\/em>.\u201d<\/p>\n

\n Q<\/strong>
\n 3<\/strong>
\n 2020 Highlights and Recent Developments<\/strong>\n <\/p>\n